ZA202202320B - Oral pharmaceutical composition containing heterocyclic compound - Google Patents

Oral pharmaceutical composition containing heterocyclic compound

Info

Publication number
ZA202202320B
ZA202202320B ZA2022/02320A ZA202202320A ZA202202320B ZA 202202320 B ZA202202320 B ZA 202202320B ZA 2022/02320 A ZA2022/02320 A ZA 2022/02320A ZA 202202320 A ZA202202320 A ZA 202202320A ZA 202202320 B ZA202202320 B ZA 202202320B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
composition containing
heterocyclic compound
containing heterocyclic
oral pharmaceutical
Prior art date
Application number
ZA2022/02320A
Other languages
English (en)
Inventor
YOSHIMURA Motoyasu
Fujii Takuya
Kamada Naoki
TOGASHI Ryohei
AONO Ryuta
Wang Xinyu
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of ZA202202320B publication Critical patent/ZA202202320B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2022/02320A 2019-08-13 2022-02-23 Oral pharmaceutical composition containing heterocyclic compound ZA202202320B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2019/031895 WO2021029020A1 (ja) 2019-08-13 2019-08-13 経口医薬組成物
PCT/JP2020/030777 WO2021029430A1 (ja) 2019-08-13 2020-08-13 複素環化合物を含有する経口医薬組成物

Publications (1)

Publication Number Publication Date
ZA202202320B true ZA202202320B (en) 2024-06-26

Family

ID=74569440

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2022/02320A ZA202202320B (en) 2019-08-13 2022-02-23 Oral pharmaceutical composition containing heterocyclic compound
ZA2022/02319A ZA202202319B (en) 2019-08-13 2022-02-23 Oral pharmaceutical composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2022/02319A ZA202202319B (en) 2019-08-13 2022-02-23 Oral pharmaceutical composition

Country Status (15)

Country Link
US (4) US20220273647A1 (cg-RX-API-DMAC7.html)
EP (2) EP4015002A4 (cg-RX-API-DMAC7.html)
JP (7) JPWO2021029020A1 (cg-RX-API-DMAC7.html)
KR (2) KR20220046624A (cg-RX-API-DMAC7.html)
CN (2) CN114222575A (cg-RX-API-DMAC7.html)
AU (2) AU2020328351B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022002433A2 (cg-RX-API-DMAC7.html)
CA (2) CA3150827A1 (cg-RX-API-DMAC7.html)
IL (2) IL290469B2 (cg-RX-API-DMAC7.html)
MX (3) MX2022001758A (cg-RX-API-DMAC7.html)
MY (2) MY208267A (cg-RX-API-DMAC7.html)
PH (2) PH12022550349B1 (cg-RX-API-DMAC7.html)
TW (4) TWI923262B (cg-RX-API-DMAC7.html)
WO (3) WO2021029020A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202202320B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021029020A1 (cg-RX-API-DMAC7.html) * 2019-08-13 2021-02-18
WO2023145120A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 薬物放出制御製剤用組成物及び薬物放出制御製剤
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤
JP2025539974A (ja) * 2023-03-29 2025-12-11 メルク・シャープ・アンド・ドーム・エルエルシー 放出制御型pde10a製剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (cg-RX-API-DMAC7.html) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組,以及彼之用途
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
AR088372A1 (es) * 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
CN112402421A (zh) * 2012-10-25 2021-02-26 大塚制药株式会社 含有依匹唑派或其盐的预防和/或治疗剂
CN106667969A (zh) * 2017-02-23 2017-05-17 佛山市弘泰药物研发有限公司 一种依匹哌唑缓释胶囊及其制备方法
JP6886654B2 (ja) * 2017-04-11 2021-06-16 学校法人帝京大学 抗カンジダ活性組成物
JPWO2021029020A1 (cg-RX-API-DMAC7.html) * 2019-08-13 2021-02-18

Also Published As

Publication number Publication date
JP2025072595A (ja) 2025-05-09
US20250057835A1 (en) 2025-02-20
JP2022132411A (ja) 2022-09-08
MX2025006039A (es) 2025-07-01
US20220273647A1 (en) 2022-09-01
WO2021029020A1 (ja) 2021-02-18
TW202517267A (zh) 2025-05-01
CA3150827A1 (en) 2021-02-18
JPWO2021029430A1 (cg-RX-API-DMAC7.html) 2021-02-18
JPWO2021029020A1 (cg-RX-API-DMAC7.html) 2021-02-18
TWI870441B (zh) 2025-01-21
JP7110495B2 (ja) 2022-08-01
CN114222562A (zh) 2022-03-22
EP4015002A1 (en) 2022-06-22
IL290469B2 (en) 2025-08-01
JP7148733B2 (ja) 2022-10-05
IL290469A (en) 2022-04-01
BR112022002436A2 (pt) 2022-12-13
MY208267A (en) 2025-04-29
AU2020327792B2 (en) 2026-03-05
TWI915169B (zh) 2026-02-11
ZA202202319B (en) 2024-06-26
KR20220046624A (ko) 2022-04-14
EP4015001A4 (en) 2023-06-14
TW202517266A (zh) 2025-05-01
MX2022001759A (es) 2022-05-13
CN114222575A (zh) 2022-03-22
MY208261A (en) 2025-04-29
PH12022550349A1 (en) 2022-12-12
MX2022001758A (es) 2022-05-13
WO2021029429A1 (ja) 2021-02-18
WO2021029430A1 (ja) 2021-02-18
BR112022002433A2 (pt) 2022-12-13
TWI923262B (zh) 2026-04-21
AU2020328351B2 (en) 2026-03-05
PH12022550347A1 (en) 2022-12-12
EP4015002A4 (en) 2023-06-07
JP2025074104A (ja) 2025-05-13
JP7635187B2 (ja) 2025-02-25
PH12022550349B1 (en) 2024-03-06
AU2020328351A1 (en) 2022-03-24
KR20220046625A (ko) 2022-04-14
EP4015001A1 (en) 2022-06-22
AU2020327792A1 (en) 2022-03-24
JP2022180531A (ja) 2022-12-06
IL290469B1 (en) 2025-04-01
TW202120091A (zh) 2021-06-01
JPWO2021029429A1 (cg-RX-API-DMAC7.html) 2021-02-18
US20220280418A1 (en) 2022-09-08
CA3150751A1 (en) 2021-02-18
TW202120090A (zh) 2021-06-01
US20250127776A1 (en) 2025-04-24
TWI870442B (zh) 2025-01-21
IL290472A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
EP4685160A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12022550349B1 (en) Oral pharmaceutical composition containing heterocyclic compound
EP4512394A3 (en) Dosage forms and use thereof
MX2021002640A (es) Formas morficas de los inhibidores del factor d del complemento.
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
ECSP045238A (es) Forma de dosis oral que contiene un inhibidor de pde 4 como un ingrediente activo y polivinilpirrolidona como excipiente
AU2016354007A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MX386033B (es) Agente terapéutico para enfermedades hepáticas.
EP3946547A4 (en) DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
EP3789040A4 (en) PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
PH12022551468A1 (en) Compounds active towards nuclear receptors
JOP20190198B1 (ar) تركيبة صيدلانية تشتمل على عامل مضاد للصفيحات ومثبط إفراز حمض معدي
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
NO20071806L (no) Tabletter med steds- og tidsregulert gastrointestinal frigivelse av aktiv bestanddel.
MX2021010207A (es) Formulacion farmaceutica de liberacion extendida.
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
IL283405A (en) Formulations, methods, kits and dosage forms to improve the stability of an active medicinal component
MX2018000963A (es) Composicion farmaceutica sinergica del enantiomero activo s-ketorolaco trometamina y clorhidrato de tramadol.
JOP20230099A1 (ar) تركيبات صيدلية
MX2019008847A (es) Profarmacos de cisteamina.
MX2022002038A (es) Composicion farmaceutica para el tratamiento del insomnio.
PH12020550456A1 (en) Alcohol-resistant oral pharmaceutical compositions of lorazepam